Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ProQR ( (PRQR) ) just unveiled an update.
On April 30, 2026, ProQR Therapeutics announced the nomination of Dr. Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, to its board of directors as an independent non-executive member, pending shareholder approval at the upcoming annual meeting. The appointment of the veteran drug-development executive, who has held senior roles at Novartis, AstraZeneca, Roche, Novo Nordisk and Lundbeck, is intended to bolster ProQR’s governance and strategic capabilities as it advances its Axiomer RNA editing pipeline and positions itself more firmly within the competitive RNA therapeutics landscape.
The move underscores ProQR’s efforts to deepen clinical and regulatory expertise on its board, a key consideration for investors watching the company’s transition from platform development toward broader clinical execution. With more than two decades of global leadership across oncology, cardiometabolic, immunology, CNS and rare diseases, Dr. Hinsch Gylvin’s experience is expected to support ProQR’s next phase of growth and could enhance confidence among partners and stakeholders in the company’s long-term development strategy.
The most recent analyst rating on (PRQR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
The score is held back primarily by weak financial performance (persistent losses and renewed heavy cash burn) and a negative P/E that underscores lack of profitability. Technicals provide some support due to improving price momentum above key moving averages.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer RNA base-editing platform. The Netherlands- and U.S.-based group aims to create a new class of medicines for rare and prevalent diseases with high unmet medical need by harnessing endogenous ADAR enzymes to make precise single-nucleotide edits in RNA.
Average Trading Volume: 528,356
Technical Sentiment Signal: Sell
Current Market Cap: $162.3M
See more insights into PRQR stock on TipRanks’ Stock Analysis page.